Sign inJoin waitlistJoin the waitlist

Anthony P. Heaney

Associate Professor · David Geffen School of Medicine at the University of California, Los Angeles

Credentials: · · · · · ·

History

David Geffen School of Medicine at the University of California, Los Angeles
Present

Cedars-Sinai Medical Center
Until 2001
Cedars-Sinai Medical Center
Until 2000
Manchester Royal Infirmary
Until 1997
Leeds General Infirmary
Until 1995
Royal Victoria Hospital
Until 1994
Royal Victoria Hospital
Until 1992
Royal Victoria Hospital
Until 1990
Royal Victoria Hospital
Until 1990
Royal Victoria Hospital
Until 1989
Mater Infirmorum Hospital
Until 1989
Mater Infirmorum Hospital
Until 1988
Queen's Univ. Belfast, School of Medicine
1987

Research

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 538 citations
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
Review · European Journal of Endocrinology · 2018 · 452 citations
Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas
The Journal of Clinical Endocrinology & Metabolism · 1999 · 336 citations

Marvin Bergsneider
31 papers
Marilene Wang
24 papers
Shlomo Melmed
19 papers
William Yong
15 papers
MF
Maria Fleseriu
8 papers
Harry Vinters
6 papers
Beverly Biller
5 papers · 1 as a fellow
Jeffrey Suh
5 papers
JS
Jonathan Strosberg
5 papers
Roberto Salvatori
5 papers
Anat Ben-Shlomo
4 papers · 1 as a fellow
AB
Ariel Barkan
4 papers

Grants

Fimepinostat, Combination HDAC and Pi3-Kinase Inhibitor Tumor-Directed Therapy for Cushing Disease (IND 168501 - 07/31/2023)
Food and Drug Administration · R01
Contact PI · $842.6K · University of California Los Angeles
2024–2029
Towards Safe and Efficacious Medical Therapy for Patients with Clinically Non-Functioning Pituitary Tumors
National Cancer Institute · R01
Contact PI · $475.4K · University of California Los Angeles
2026–2029
Development of 3-Dimensional Human Pituitary Corticotroph Tumor Cultures as a Preclinical Model for Drug Discovery
National Cancer Institute · R01
Contact PI · $1.8M · University of California Los Angeles
2021–2027
Development of a Patient-Derived Tumoroid Culture System to Explore Novel Medical Treatments for Refractory Prolactinomas
National Cancer Institute · R21
Contact PI · $392K · University of California Los Angeles
2023–2025

Clinical trials

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
Principal investigator · Terminated · Phase 2
Jonsson Comprehensive Cancer Center
2007–2010
Rosiglitazone in Treating Patients With Pituitary Tumors
Principal investigator · Terminated · Phase 2
Jonsson Comprehensive Cancer Center
2006–2010
Temozolomide in Treating Patients With Invasive Pituitary Tumors
Study chair · Withdrawn · Phase 2
Jonsson Comprehensive Cancer Center
2009